Antigen binding molecules specific for an anti-CD19 scFv

Patent metadata

Field	Value
Publication number	US-11384155-B2
Application number	US-202016814661-A
Country	US
Kind code	B2
Filing date	Mar 10, 2020
Priority date	Sep 28, 2016
Publication date	Jul 12, 2022
Grant date	Jul 12, 2022

Abstract

Isolated antigen binding molecules that specifically bind to an anti-CD19 scFv comprising SEQ ID NO: 1 are provided. The antigen binding molecules can be used in the methods provided herein.

First claim

What is claimed is:

1. An isolated antigen binding molecule that specifically binds a molecule comprising SEQ ID NO: 1, the isolated antigen binding molecule comprising:
(a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 5;
(b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 6;
(c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 7;
(d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 11;
(e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 12; and
(f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 13.

2. The antigen binding molecule of claim 1 , wherein the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′) 2 , a mouse antibody, a rat antibody, a non-human primate antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.

3. The antigen binding molecule of claim 2 , further comprising a heavy chain variable region (VH) sequence selected from the group consisting of SEQ ID NOs: 3 and 15.

4. An antigen binding molecule, which comprises a VH amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule of claim 3 .

5. The antigen binding molecule of claim 2 , further comprising a light chain variable region (VL) sequence selected from the group consisting of SEQ ID Nos: 9 and 18.

6. An antigen binding molecule, which comprises a VL amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL of an antigen binding molecule of claim 5 .

7. The antigen binding molecule of claim 2 , wherein the antigen binding molecule comprises:
(a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 9.

8. The antigen binding molecule of claim 2 , wherein the antigen binding molecule comprises:
(a) a VH comprising the amino acid sequence of SEQ ID NO: 15; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 18.

9. The antigen binding molecule of claim 1 , wherein the antigen binding molecule further comprises a detectable label.

10. The antigen binding molecule of claim 9 , wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

11. The antigen binding molecule of claim 10 , wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.

12. A composition comprising the antigen binding molecule of claim 1 .

Assignees

• Kite Pharma Inc

Inventors

• Wiltzius Jed
• SIEVERS Stuart

Classifications

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• A61K39/0011

  Cancer antigens · CPC title

• A61K2039/5156

  expressing foreign proteins · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title